- Home
- RIGL vs GWRS Comparison
RIGL vs GWRS Comparison
Compare RIGL & GWRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- GWRS
- Stock Information
- Founded
- RIGL 1996
- GWRS 2003
- Country
- RIGL United States
- GWRS United States
- Employees
- RIGL N/A
- GWRS N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- GWRS Water Supply
- Sector
- RIGL Health Care
- GWRS Utilities
- Exchange
- RIGL Nasdaq
- GWRS Nasdaq
- Market Cap
- RIGL 335.5M
- GWRS 286.0M
- IPO Year
- RIGL 2000
- GWRS 2010
- Fundamental
- Price
- RIGL $18.28
- GWRS $10.55
- Analyst Decision
- RIGL Buy
- GWRS
- Analyst Count
- RIGL 5
- GWRS 0
- Target Price
- RIGL $36.40
- GWRS N/A
- AVG Volume (30 Days)
- RIGL 170.2K
- GWRS 46.1K
- Earning Date
- RIGL 08-05-2025
- GWRS 08-06-2025
- Dividend Yield
- RIGL N/A
- GWRS 2.85%
- EPS Growth
- RIGL N/A
- GWRS N/A
- EPS
- RIGL 2.08
- GWRS 0.23
- Revenue
- RIGL $203,077,000.00
- GWRS $53,539,000.00
- Revenue This Year
- RIGL $14.41
- GWRS $8.31
- Revenue Next Year
- RIGL $15.97
- GWRS $6.52
- P/E Ratio
- RIGL $8.92
- GWRS $46.43
- Revenue Growth
- RIGL 70.16
- GWRS 3.94
- 52 Week Low
- RIGL $7.48
- GWRS $9.37
- 52 Week High
- RIGL $29.82
- GWRS $13.98
- Technical
- Relative Strength Index (RSI)
- RIGL 37.91
- GWRS 55.19
- Support Level
- RIGL $18.35
- GWRS $10.24
- Resistance Level
- RIGL $19.21
- GWRS $10.79
- Average True Range (ATR)
- RIGL 0.89
- GWRS 0.25
- MACD
- RIGL -0.33
- GWRS 0.03
- Stochastic Oscillator
- RIGL 2.15
- GWRS 62.11
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About GWRS Global Water Resources Inc.
Global Water Resources Inc operates as a water resources management company that owns, operates, and manages water, wastewater, and recycled water utilities in strategically located communities, principally in metropolitan Phoenix, Arizona. It operates within the State of Arizona.